Clinical Hematology International最新文献

Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review 造血干细胞移植中的输血支持：当代叙事回顾

Clinical Hematology International Pub Date : 2024-03-25 DOI: 10.46989/001c.94135

Brian D. Adkins, J. Jacobs, Garrett S. Booth, Bipin N Savani, Laura D. Stephens

引用次数: 0

Sinus bradycardia as a rare adverse event in patients receiving cyclosporine A after allogeneic hematopoietic stem cell transplantation. 窦性心动过缓是异体造血干细胞移植后接受环孢素 A 患者的一种罕见不良反应。

Clinical Hematology International Pub Date : 2024-03-04 DOI: 10.46989/001c.94362

M. Karasek, Maciej Majcherek, Bartłomiej Kuszczak, A. Szeremet, Olga Chyrko, Tomasz Wróbel, A. Czyż

{"title":"Sinus bradycardia as a rare adverse event in patients receiving cyclosporine A after allogeneic hematopoietic stem cell transplantation.","authors":"M. Karasek, Maciej Majcherek, Bartłomiej Kuszczak, A. Szeremet, Olga Chyrko, Tomasz Wróbel, A. Czyż","doi":"10.46989/001c.94362","DOIUrl":"https://doi.org/10.46989/001c.94362","url":null,"abstract":"Cyclosporine A (CSA) is a commonly used immunosuppressive agent for the prophylaxis of graft-versus-host disease following allogeneic hematopoietic stem cell transplantation (alloHSCT). While tachycardia is a known adverse effect of CSA, bradycardia remains a phenomenon rarely described in the literature. We conducted a retrospective evaluation of the incidence of bradycardia in patients after alloHSCT treated with CSA between January 2020 and February 2023 at our center. Out of 206 patients, sinus bradycardia following the administration of CSA was observed in 6 (2.9%), comprising 3 women and 3 men, with the median age of 55 years (range: 20-65). The underlying diseases were myeloid malignancies in 4 and aggressive lymphoma in 2 patients. The patients received grafts from a matched unrelated (n=5) or a haploidentical family donor (n=1) following various conditioning regimens. Coexisting cardiovascular disorders were found in 5 of the 6 patients. All patients experienced symptomatic bradycardia within 1-4 days (median 2 days) after CSA introduction, which persisted until CSA withdrawal. One patient required treatment with atropine. All patients continued their immunosuppressive therapy with tacrolimus, which was well-tolerated Our study indicates CSA as a causative factor of sinus bradycardia in a small percentage of alloHSCT patients receiving CSA as graft-versus host disease (GvHD) prophylaxis. Importantly, these patients did not experience any cardiac complications when switched to tacrolimus. Although further research on the effects of CSA on heart automatation is needed, our single-center experience can help prompt diagnosis and therapeutic intervention in daily clinical practice.","PeriodicalId":503947,"journal":{"name":"Clinical Hematology International","volume":"55 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140080749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Walking ability in adults with severe hemophilia: A cross-sectional study 重症血友病成人的行走能力：横断面研究

Clinical Hematology International Pub Date : 2024-03-03 DOI: 10.46989/001c.94374

Malika Jhandai, Dimple Choudhry, Sudhir Kumar Atri, Pankaj Bhardwaj, Kusum Yadav

{"title":"Walking ability in adults with severe hemophilia: A cross-sectional study","authors":"Malika Jhandai, Dimple Choudhry, Sudhir Kumar Atri, Pankaj Bhardwaj, Kusum Yadav","doi":"10.46989/001c.94374","DOIUrl":"https://doi.org/10.46989/001c.94374","url":null,"abstract":"A lack of factor VIII (FVIII) or factor IX (FIX) results in hemophilia, a blood-clotting illness. The mode of inheritance is chromosome X-linked and recessive. The primary symptom of severe hemophilia is spontaneous and recurrent bleeding into joints, muscles, and soft tissues. Unpreventable bleeding may cause arthropathy, chronic discomfort, and muscular atrophy. Therefore, joints’ functional loss affects the functional and walking ability. The aim of this study was to determine the walking ability by measuring the 50-m walk test time in severe hemophilic patients, as compared to the normal population. Sixty subjects (males) in the 18-30 year age group were selected and comprised 30 hemophiliacs and 30 in a control group. The 50-m walking ability was measured in seconds. The results showed a normative value of 36.6 sec in the control and 67.2 sec in the hemophilic group. Statistical analysis of the data showed that the walking ability was significantly reduced in the hemophilic group. These normative values illustrate a useful, simple, reproducible, rapid assessment of walking disability in adults with hemophilic arthropathy, and also aid the planning of treatment.","PeriodicalId":503947,"journal":{"name":"Clinical Hematology International","volume":"8 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140081199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review 中东和非洲多发性骨髓瘤的流行病学、治疗趋势和结果：系统回顾

Clinical Hematology International Pub Date : 2024-02-22 DOI: 10.46989/001c.92555

Mervat Mattar, Ali Bazarbachi, Omar Abduljalil, Bassam Francis, Arif Alam, Vivian Blunk

{"title":"Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review","authors":"Mervat Mattar, Ali Bazarbachi, Omar Abduljalil, Bassam Francis, Arif Alam, Vivian Blunk","doi":"10.46989/001c.92555","DOIUrl":"https://doi.org/10.46989/001c.92555","url":null,"abstract":"Globally, multiple myeloma (MM) ranks 24th among the most common cancers. The Middle East and Africa are affected by an increasing trend in MM incidence, owing to several underlying factors. This systematic review aims to assess the epidemiology, patient characteristics, and treatment outcomes associated with MM in selected countries in the Middle East and Africa. An electronic search was performed in the PubMed/MEDLINE database. Abstracts presented at the annual meetings of the American Society of Clinical Oncology, American Society of Hematology, and European Society for Medical Oncology and the GLOBOCAN registry were searched. Qualitative analysis was performed. A total of 412 articles were screened, and 14 were selected. The five-year prevalence per 100,000 gathered from country-wise GLOBOCAN data ranged between 155 in Kuwait and 5,625 in North Africa. The identified treatment options were proteasome inhibitors such as bortezomib, drugs such as thalidomide, lenalidomide, dexamethasone, melphalan, and cyclophosphamide, and newer drugs such as daratumumab. Improved diagnostic capability has increased the incidence of MM in this region. However, advanced drugs and treatment regimens remain unaffordable in many countries of these regions. Therefore, understanding the trends of the disease and improving healthcare settings are imperative.","PeriodicalId":503947,"journal":{"name":"Clinical Hematology International","volume":"28 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140438451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early de-escalation of antibiotic therapy in hospitalized cellular therapy adult patients with febrile neutropenia 发热性中性粒细胞减少症住院细胞疗法成人患者抗生素治疗的早期降级

Clinical Hematology International Pub Date : 2024-02-22 DOI: 10.46989/001c.94105

M. Lucena, Kelly J. Gaffney, Theresa A. Urban, Catherine Forbes, Pavithra Srinivas, N. Majhail, E. Cober, S. Mossad, Lisa Rybicki, B. Hamilton

{"title":"Early de-escalation of antibiotic therapy in hospitalized cellular therapy adult patients with febrile neutropenia","authors":"M. Lucena, Kelly J. Gaffney, Theresa A. Urban, Catherine Forbes, Pavithra Srinivas, N. Majhail, E. Cober, S. Mossad, Lisa Rybicki, B. Hamilton","doi":"10.46989/001c.94105","DOIUrl":"https://doi.org/10.46989/001c.94105","url":null,"abstract":"Febrile neutropenia (FN) is an oncologic emergency frequently encountered in hematopoietic cell transplant (HCT) and chimeric antigen receptor (CAR) T-cell therapy patients, which requires immediate initiation of broad-spectrum antibiotics. Data regarding antibiotic de-escalation (DE) in neutropenic patients are limited, and guideline recommendations vary. A clinical protocol for antibiotic DE of broad-spectrum agents was implemented if patients were afebrile after 72 hours and had no clinical evidence of infection. The primary endpoint was the difference in the number of antibiotic therapy days between the pre-and post-DE protocol implementation group. Secondary endpoints included rates of subsequent bacteremia during index hospitalization, 30-day mortality, and hospital length of stay. Retrospective chart reviews were conducted to assess outcomes for patients who received allogeneic HCT, autologous HCT, or CAR T-cell therapy under the antibiotic de-escalation protocol (post-DE) compared to those who did not (pre-DE). The pre-DE group underwent HCT/CAR T-cell from February 2018 through September 2018 (n=64), and the post-DE group from February 2019 through September 2019 (n=67). The median duration of antibiotics was significantly lower in the post-DE group (6 days; range 3-60 days) compared to the pre-DE group (8 days; range 3-31 days) (p=0.034). There were no differences in any secondary endpoints. We conclude that antibiotic DE in neutropenic HCT or CAR T-cell therapy patients treated with broad-spectrum antibiotics for at least three days who are afebrile and without documented infection appears to be a safe and effective practice. Adopting it significantly reduces the number of days of antibiotics without compromising patient outcomes.","PeriodicalId":503947,"journal":{"name":"Clinical Hematology International","volume":"57 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140439652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Vertebral Augmentation Procedures in the Management of Multiple Myeloma 椎体增强术在多发性骨髓瘤治疗中的作用

Clinical Hematology International Pub Date : 2024-02-20 DOI: 10.46989/001c.92984

N. Thalambedu, Mudassar Kamran, Samer Al-Hadidi

引用次数: 0

Supportive Care of Hematopoietic Stem Cell Donors 造血干细胞捐献者的支持性护理

Clinical Hematology International Pub Date : 2024-02-20 DOI: 10.46989/001c.92460

Wolfgang P Rennert, Jenna Smith M, Katie Cormier, Anne E Austin

{"title":"Supportive Care of Hematopoietic Stem Cell Donors","authors":"Wolfgang P Rennert, Jenna Smith M, Katie Cormier, Anne E Austin","doi":"10.46989/001c.92460","DOIUrl":"https://doi.org/10.46989/001c.92460","url":null,"abstract":"Supportive care needs for hematopoietic stem cell recipients have been studied. Less is known about the care needs of stem cell donors. Care challenges arise at donor selection, preparation for the donation, the donation procedure and the immediate and long-term after-care. Care needs were analyzed for 1,831 consecutive bone marrow and peripheral stem cell donors at MedStar Georgetown University Hospital between January 2018 and August 2023 in support of a review of the current literature. During the selection, related donors may experience psychological pressures affecting their motivation, while donation centers may be willing to accept co-morbidities in these donors which might preclude donation in unrelated peers. For bone marrow donations, it is important to select donors not only according to optimal genetic matching criteria but also according to suitable donor/recipient weight ratios, to facilitate sufficient stem cell yields. During the donation preparation phase, side effects and complications related to stem cell stimulation must be anticipated and managed for peripheral cell donors, while the pros and cons of autologous blood donation should be evaluated carefully for bone marrow donors. The stem cell donation procedure itself carries potential side effects and complications as well. Peripheral cell donors may require a central line and may encounter hypocalcemia, thrombocytopenia, and anemia. Bone marrow donors face risks associated with anesthesia, blood loss and pain. Post-procedure care focusses on pain management, blood cell recovery and the psychological support necessary to regain a high quality-of-life existence. Hematopoietic stem donors are giving part of themselves to save another’s life. They deserve comprehensive supportive care to accompany them throughout the donation process.","PeriodicalId":503947,"journal":{"name":"Clinical Hematology International","volume":"374 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140447925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standing on the Shoulders of the Giants: Dr. Kenneth Anderson 站在巨人的肩膀上肯尼思-安德森博士

Clinical Hematology International Pub Date : 2024-02-05 DOI: 10.46989/001c.92692

M. Mohty, Kenneth C. Anderson

引用次数: 0

Standing on the Shoulders of the Giants: Dr. Kenneth Anderson 站在巨人的肩膀上肯尼思-安德森博士

Clinical Hematology International Pub Date : 2024-02-05 DOI: 10.46989/001c.92692

M. Mohty, Kenneth C. Anderson

引用次数: 0

Human herpesvirus type 6 reactivation after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide and antithymocyte globulin: risk factors and clinical impact 使用移植后环磷酰胺和抗胸腺细胞球蛋白进行单倍体造血细胞移植后人类疱疹病毒6型再激活：风险因素和临床影响

Clinical Hematology International Pub Date : 2024-02-02 DOI: 10.46989/001c.92525

A. Paviglianiti, Tânia Maia, Joël-Meyer Gozlan, E. Brissot, F. Malard, Anne Banet, Zoé Van de Wyngaert, T. Ledraa, R. Belhocine, S. Sestili, Antoine Capes, Nicolas Stocker, Agnès Bonnin, A. Vekhoff, Ollivier Legrand, M. Mohty, R. Duléry

{"title":"Human herpesvirus type 6 reactivation after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide and antithymocyte globulin: risk factors and clinical impact","authors":"A. Paviglianiti, Tânia Maia, Joël-Meyer Gozlan, E. Brissot, F. Malard, Anne Banet, Zoé Van de Wyngaert, T. Ledraa, R. Belhocine, S. Sestili, Antoine Capes, Nicolas Stocker, Agnès Bonnin, A. Vekhoff, Ollivier Legrand, M. Mohty, R. Duléry","doi":"10.46989/001c.92525","DOIUrl":"https://doi.org/10.46989/001c.92525","url":null,"abstract":"Human herpesvirus type 6 (HHV6) reactivation after haploidentical hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PT-Cy) has been scarcely studied, especially when antithymocyte globulin (ATG) is added to the graft-versus-host disease (GvHD) prophylaxis. We conducted a retrospective cohort study in 100 consecutive patients receiving haploidentical HCT with PT-Cy. We systematically monitored HHV6 DNA loads in blood samples on a weekly basis using quantitative PCR until day +100. The 100-day cumulative incidence of HHV6 reactivation was 54%. Clinically significant HHV6 infections were rare (7%), associated with higher HHV6 DNA loads, and had favorable outcomes after antiviral therapy. The main risk factor for HHV6 reactivation was a low absolute lymphocyte count (ALC) < 290/µL on day +30 (68% versus 40%, p = 0.003). Adding ATG to PT-Cy did not increase the incidence of HHV6 reactivation (52% with ATG versus 79% without ATG, p = 0.12). Patients experiencing HHV6 reactivation demonstrated delayed platelet recovery (HR 1.81, 95% CI 1.07-3.05, p = 0.026), higher risk of acute grade II-IV GvHD (39% versus 9%, p < 0.001) but similar overall survival and non-relapse mortality to the other patients. In conclusion, our findings endorse the safety of combining ATG and PT-Cy in terms of the risk of HHV6 reactivation and infection in patients undergoing haploidentical HCT. Patients with a low ALC on day +30 face a higher risk of HHV6 reactivation and may require careful monitoring.","PeriodicalId":503947,"journal":{"name":"Clinical Hematology International","volume":"62 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139869911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0